Skip to main content

LTE of deucravacitinib trials in psoriasis. Remarkable & frankly surprising (to me) persistence of benefitVery enc

Social Author Name
Mike Putman
Tweet Content

LTE of deucravacitinib trials in psoriasis. Remarkable & frankly surprising (to me) persistence of benefit Very encouraging for patients who start TYKs, looks like those who respond may have prolonged benefit #ACR24 @RheumNow Abstr#0290 #ACRBest https://t.co/kao4vqpPTQ

Show on Archive Page
On
Display in Search Results
On
PDQ
On
×